Shots: The US FDA has granted PR to Takeda’s sNDA for the expanded use of Alunbrig (brigatinib) as 1L treatment for patients with ALK+ metastatic NSCLC detected by FDA-approved test […]readmore
Tags : ALK + Metastatic Non-Small Cell Lung Cancer